Rare diseases
Investigational molecules
Locations
706 conditions with trials, the busiest first
3 926 trials across Europe, recruiting first
Study of Atezolizumab and RP1 for Patients with Early-Stage Triple-Negative Breast Cancer
FranceStudy of RO7247669 and Nab-Paclitaxel vs. Pembrolizumab and Nab-Paclitaxel for Patients with Untreated, PD-L1 Positive, Advanced Triple-Negative Breast Cancer
CzechiaStudy Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy
AustriaStudy of Ripretinib vs Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumor with Specific KIT Exon Mutations Previously Treated with Imatinib
FranceStudy of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer
AustriaStudy of Tislelizumab, LBL-007, and BGB-15025 in Patients with Advanced Non-Small Cell Lung Cancer
FranceStudy Comparing Tisagenlecleucel with Standard Treatment for Adults with Relapsed or Refractory Follicular Lymphoma
AustriaStudy on the Safety and Effectiveness of REGN7075 and Cemiplimab, with or without Chemotherapy, for Patients with Advanced Solid Tumors
FranceStudy on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma
AustriaStudy of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma
DenmarkStudy of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma
CroatiaStudy of Pembrolizumab and Chemotherapy for Patients with Newly Diagnosed Classical Hodgkin Lymphoma
FranceThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
